• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

地拉韦啶联合齐多夫定治疗1型人类免疫缺陷病毒感染患者：一项随机、对照III期试验中的疗效评估及病毒耐药性的出现。M/3331/0013B研究组

Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group.

作者信息

Joly V, Moroni M, Concia E, Lazzarin A, Hirschel B, Jost J, Chiodo F, Bentwich Z, Love W C, Hawkins D A, Wilkins E G, Gatell A J, Vetter N, Greenwald C, Freimuth W W, de Cian W

机构信息

Department of Internal Medicine, Hôpital Bichat, Paris, France.

出版信息

Antimicrob Agents Chemother. 2000 Nov;44(11):3155-7. doi: 10.1128/AAC.44.11.3155-3157.2000.

DOI:10.1128/AAC.44.11.3155-3157.2000
PMID:11036040
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC101620/
Abstract

We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.

摘要

在一项随机、双盲、安慰剂对照试验中，我们比较了地拉韦啶（DLV）加齐多夫定（AZT）（n = 300）与AZT（n = 297）对1型人类免疫缺陷病毒的活性。DLV发挥了短暂的抗病毒作用，在第12周时，超过90%的受试者中发现了对地拉韦啶耐药的突变。85%的患者中发现了赋予非核苷类逆转录酶抑制剂交叉耐药性的K103N突变。

相似文献

1
Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group.地拉韦啶联合齐多夫定治疗1型人类免疫缺陷病毒感染患者：一项随机、对照III期试验中的疗效评估及病毒耐药性的出现。M/3331/0013B研究组
Antimicrob Agents Chemother. 2000 Nov;44(11):3155-7. doi: 10.1128/AAC.44.11.3155-3157.2000.
2
HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.接受去羟肌苷和地拉韦啶联合治疗的患者的HIV-1药物敏感性及逆转录酶突变
J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Feb 1;14(2):136-44. doi: 10.1097/00042560-199702010-00006.
3
Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260).在一项地拉韦定单药治疗的I/II期试验（ACTG 260）中，来自患者的1型人类免疫缺陷病毒分离株的地拉韦定敏感性及相关逆转录酶突变
Antimicrob Agents Chemother. 2000 Mar;44(3):794-7. doi: 10.1128/AAC.44.3.794-797.2000.
4
Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.在1型人类免疫缺陷病毒感染患者中，进行地拉韦啶（U-90152S）与传统核苷联合治疗的随机对照I/II期试验。
Antimicrob Agents Chemother. 1996 Jul;40(7):1657-64. doi: 10.1128/AAC.40.7.1657.
5
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.非核苷类逆转录酶抑制剂治疗失败患者病毒分离株中对依非韦伦表型耐药的基因型相关性
J Virol. 2001 Jun;75(11):4999-5008. doi: 10.1128/JVI.75.11.4999-5008.2001.
6
The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities.P236L地拉韦定耐药的1型人类免疫缺陷病毒突变体复制存在缺陷，并且在RNA 5'端和DNA 3'端导向的核糖核酸酶H活性方面均表现出改变。
J Virol. 1999 Jul;73(7):5803-13. doi: 10.1128/JVI.73.7.5803-5813.1999.
7
Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. HBY 097/2001 Study Group.人免疫缺陷病毒1型特异性非核苷类逆转录酶抑制剂HBY 097单独及与齐多夫定联合应用的抗病毒活性：一项II期研究。HBY 097/2001研究组
J Infect Dis. 1999 Mar;179(3):709-13. doi: 10.1086/314633.
8
Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.临床逆转录酶序列对HIV-1耐药突变体复制能力的影响。
Virology. 2001 Jul 5;285(2):193-203. doi: 10.1006/viro.2001.0920.
9
Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.茚地那韦、利托那韦和地拉韦啶与核苷类逆转录酶抑制剂联合治疗经多种抗逆转录病毒联合治疗失败的HIV/AIDS患者。
HIV Clin Trials. 2001 May-Jun;2(3):193-9. doi: 10.1310/LJ7M-82QX-5QJJ-1R6R.
10
Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial.地拉韦定与齐多夫定联合治疗的疗效和安全性：一项欧洲/澳大利亚II期试验。
Int J Antimicrob Agents. 1999 Jan;11(1):13-21. doi: 10.1016/s0924-8579(98)00082-x.

引用本文的文献

1
The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy.长期含奈韦拉平抗病毒治疗中耐药突变 K103N Y181C 和 G190A 的发展。
AIDS Res Ther. 2014 Nov 21;11:36. doi: 10.1186/1742-6405-11-36. eCollection 2014.
2
HIV drug resistance and its impact on antiretroviral therapy in Chinese HIV-infected patients.HIV 耐药性及其对中国 HIV 感染患者抗逆转录病毒治疗的影响。
PLoS One. 2013;8(2):e54917. doi: 10.1371/journal.pone.0054917. Epub 2013 Feb 6.
3
The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.HIV-1对逆转录酶和蛋白酶抑制剂耐药性的遗传基础。
AIDS Rev. 2000;2(4):211-228.
4
Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs.在转而接受不含非核苷类逆转录酶抑制剂（NNRTIs）的抗逆转录病毒治疗的HIV-1感染患者中，人类免疫缺陷病毒1型（HIV-1）对NNRTIs耐药突变的演变情况。
Antimicrob Agents Chemother. 2004 Jan;48(1):172-5. doi: 10.1128/AAC.48.1.172-175.2004.
5
Genotypic testing for human immunodeficiency virus type 1 drug resistance.1型人类免疫缺陷病毒耐药性的基因检测
Clin Microbiol Rev. 2002 Apr;15(2):247-77. doi: 10.1128/CMR.15.2.247-277.2002.

本文引用的文献

1
Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260).在一项地拉韦定单药治疗的I/II期试验（ACTG 260）中，来自患者的1型人类免疫缺陷病毒分离株的地拉韦定敏感性及相关逆转录酶突变
Antimicrob Agents Chemother. 2000 Mar;44(3):794-7. doi: 10.1128/AAC.44.3.794-797.2000.
2
The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities.P236L地拉韦定耐药的1型人类免疫缺陷病毒突变体复制存在缺陷，并且在RNA 5'端和DNA 3'端导向的核糖核酸酶H活性方面均表现出改变。
J Virol. 1999 Jul;73(7):5803-13. doi: 10.1128/JVI.73.7.5803-5813.1999.
3
ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team.ACTG 260：一项关于地拉韦定单药治疗抗人类免疫缺陷病毒活性的随机、I-II期、剂量范围试验。艾滋病临床试验组方案260团队。
Antimicrob Agents Chemother. 1999 Jun;43(6):1373-8. doi: 10.1128/AAC.43.6.1373.
4
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.一项针对每立方毫米CD4细胞计数为200至500的HIV感染成人，比较核苷单药疗法与联合疗法的试验。艾滋病临床试验组研究175研究团队。
N Engl J Med. 1996 Oct 10;335(15):1081-90. doi: 10.1056/NEJM199610103351501.
5
Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.在1型人类免疫缺陷病毒感染患者中，进行地拉韦啶（U-90152S）与传统核苷联合治疗的随机对照I/II期试验。
Antimicrob Agents Chemother. 1996 Jul;40(7):1657-64. doi: 10.1128/AAC.40.7.1657.
6
A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group.
AIDS. 1996 Jun;10(6):635-41. doi: 10.1097/00002030-199606000-00009.
7
Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.德尔塔：一项随机双盲对照试验，比较齐多夫定加去羟肌苷或扎西他滨联合用药与单用齐多夫定在HIV感染者中的疗效。德尔塔协调委员会。
Lancet. 1996 Aug 3;348(9023):283-91.
8
Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.奈韦拉平、齐多夫定和去羟肌苷与齐多夫定和去羟肌苷治疗HIV-1感染患者的比较。一项随机、双盲、安慰剂对照试验。美国国立过敏与传染病研究所艾滋病临床试验组方案241研究者。
Ann Intern Med. 1996 Jun 15;124(12):1019-30. doi: 10.7326/0003-4819-124-12-199606150-00001.